{"id":206302,"date":"2022-10-31T10:00:00","date_gmt":"2022-10-31T09:00:00","guid":{"rendered":"https:\/\/www.bluenovius.com\/?p=206302"},"modified":"2022-10-12T13:08:51","modified_gmt":"2022-10-12T11:08:51","slug":"can-clinical-trials-be-rebuilt-based-on-patients-needs","status":"publish","type":"post","link":"https:\/\/www.bluenovius.com\/pharma-challenges\/the-new-normal\/can-clinical-trials-be-rebuilt-based-on-patients-needs\/","title":{"rendered":"Can Clinical Trials Be Rebuilt Based on Patients’ Needs?"},"content":{"rendered":"\n
<\/div>\n\n\n
\n
\"pharma-changes-can-clinical-trials-be-rebuilt-based-on-patient-needs\"<\/a><\/figure><\/div>\n\n\n
<\/div>\n\n\n\n

Technology is taking over as a leading actor in pharma. This is making \u201ccustomer-centric\u201d<\/strong> the new word of order for the industry\u2019s digital revolution. In their turn, clinical trials are not immune to the looming changes. <\/p>\n\n\n\n

Patients, as highly digitalized, empowered consumers are redefining pharma\u2019s paradigm and pushing forward new questions. Can pharma companies rebuild clinical trials around patient needs? A recent report by Reuters Events presents an interesting insight into this question.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Stakeholders’ Growing Importance in Clinical Trials<\/h2>\n\n\n\n
<\/div>\n\n\n\n

Pharma will have to become more customer-centric<\/a> to survive the rising digital era. This is why consumers\u2019 needs (or in this case, the stakeholders’) are being taken into consideration. <\/p>\n\n\n\n

Pharma has been collaborating with other companies to improve the processes of clinical trials. Yet, there is one stakeholder to consider: the patient. One way to undergo this is to enable and empower the patients<\/a> to join the conversation on clinical trials.<\/p>\n\n\n\n

To get more accurate data, pharma organizations can cooperate with different disciplines. However, for this to succeed, companies must learn from technology partners aside from a clinical setting. These can share new ways of working, introducing pharma to new insights.<\/p>\n\n\n\n

The good news is that technology partners<\/a> are increasingly taken into account on the side of healthcare. One of the main goals is to deconstruct internal processes for the benefit of the stakeholders. The experiences that other industries went through will help pharma trace its map to digital transformation.<\/p>\n\n\n\n

In that sense, the FDA (Food and Drug Administration) has issued guidance on how to enhance clinical trial diversity. It promotes the broadening of the eligibility criteria for clinical trials. There is also a recommendation on the burdens that participants face when participating in these initiatives.<\/p>\n\n\n\n

When it comes to the digital spectrum, the FDA is working on solutions to help companies integrate real-world data (RWD). This refers to data taken from:<\/p>\n\n\n\n